DO, University of Pikeville College of Osteopathic Medicine, (2021)
Intern, OhioHealth Riverside Methodist Hospital, (2022)
MS, The Ohio State University Graduate School, Anatomy (2017)
BS, The Ohio State University, Biological Sciences (2014)
Selected Honors and Awards
Excellence in Patient Care (2021)
Excellence in Research, KYCOM Award (2021)
Member, Gold Humanism Honor Society (2020)
ED to MED Outstanding Advocate of the Year Award, AACOM Government Relations (2019)
Dr. John A. Strosnider Leadership Award (2019)
Young Investigator Travel Award – Chinese Society for Clinical Oncology (2018)
Good Samaritan Service Award (2018)
American Society of Clinical Oncology Medical Student Rotation – Conquer Cancer Foundation Award (2018)
American Association for Cancer Research Scholar-in-Training Award (2018)
Pelotonia IRP Idea Grant (2016)
Boards, Advisory Committees and Professional Organizations
Member, UME-GME Transition to Residency Working Group, 2022-present
Member, AACOM’s Advisory Committee for Resilient Mindsets in Medicine, 2022-present
Membership Recruitment Chair, AOGME Residents and Fellows Council Executive Board , 2021-present
Associate Member, AOGME Residents and Fellows Council, 2021-present
American Society for Radiation Oncology, 2020-present
American College of Radiation Oncology, 2020-present
American Society of Clinical Oncology, 2019-present
Omega Beta Iota: National Osteopathic Political Honor Society, 2018-present
Sigma Sigma Phi: Osteopathic National Honors and Service Fraternity, 2018-present
Student Ambassador, ED to MED National Grassroots Advocacy Campaign, 2018-2021
Panelist, ED to MED Town Hall, AACOM Educating Leaders Conference, 2019
Delegate, Kentucky Osteopathic Medical Association, AOA House of Delegates, 2018-2019
Student Representative, University of Pikeville Board of Trustees, 2018-2019
President, Student Government Association, Kentucky College of Osteopathic Medicine, 2018-2019
Member, Social Media Steering Committee, University of Pikeville, 2018-2019
American Osteopathic Association, 2017-present
American Association for Cancer Research, 2017-2021
Sigma Xi: Scientific Research Honor Society, 2013-2019
Progressive Global Ataxia With Sensory Changes as a Paraneoplastic Syndrome in a Patient With Chromophobe Renal Cell Carcinoma Cureus
Basree MM, Rudy R, Romaniello C, Smith DE, Kander E
2022 May 11;14(5):e24913. doi: 10.7759/cureus.24913. eCollection 2022 May.
Paraneoplastic syndromes (PNS) are rare and can be challenging to diagnose and treat. The uniqueness of PNS lies in the complexity of presentation, the importance of early diagnosis, and the role of multidisciplinary care in managing those patients to mitigate long-term neurologic complications. We describe a patient with metastatic renal cell carcinoma who presented with a complex constellation of neurological symptoms (progressive global ataxia and sensory changes) that did not resolve following nephrectomy. While complete resolution of symptoms was not achieved, he did have stabilization of his neurologic decline with the initiation of cancer-directed therapies.
PMID:35698712 | PMC:PMC9187143 | DOI:10.7759/cureus.24913
View details for PubMedID 35698712
Comprehensive Review of Molecular Mechanisms and Clinical Features of Invasive Lobular Cancer The oncologist
Pramod N, Nigam A, Basree M, Mawalkar R, Mehra S, Shinde N, Tozbikian G, Williams N, Majumder S, Ramaswamy B
2021 Jun;26(6):e943-e953. doi: 10.1002/onco.13734. Epub 2021 Mar 16.
Invasive lobular carcinoma (ILC) accounts for 10% to 15% of breast cancers in the United States, 80% of which are estrogen receptor (ER)-positive, with an unusual metastatic pattern of spread to sites such as the serosa, meninges, and ovaries, among others. Lobular cancer presents significant challenges in detection and clinical management given its multifocality and multicentricity at presentation. Despite the unique features of ILC, it is often lumped with hormone receptor-positive invasive ductal cancers (IDC); consequently, ILC screening, treatment, and follow-up strategies are largely based on data from IDC. Despite both being treated as ER-positive breast cancer, querying the Cancer Genome Atlas database shows distinctive molecular aberrations in ILC compared with IDC, such as E-cadherin loss (66% vs. 3%), FOXA1 mutations (7% vs. 2%), and GATA3 mutations (5% vs. 20%). Moreover, compared with patients with IDC, patients with ILC are less likely to undergo breast-conserving surgery, with lower rates of complete response following therapy as these tumors are less chemosensitive. Taken together, this suggests that ILC is biologically distinct, which may influence tumorigenesis and therapeutic strategies. Long-term survival and clinical outcomes in patients with ILC are worse than in stage- and grade-matched patients with IDC; therefore, nuanced criteria are needed to better define treatment goals and protocols tailored to ILC's unique biology. This comprehensive review highlights the histologic and clinicopathologic features that distinguish ILC from IDC, with an in-depth discussion of ILC's molecular alterations and biomarkers, clinical trials and treatment strategies, and future targets for therapy. IMPLICATIONS FOR PRACTICE: The majority of invasive lobular breast cancers (ILCs) are hormone receptor (HR)-positive and low grade. Clinically, ILC is treated similar to HR-positive invasive ductal cancer (IDC). However, ILC differs distinctly from IDC in its clinicopathologic characteristics and molecular alterations. ILC also differs in response to systemic therapy, with studies showing ILC as less sensitive to chemotherapy. Patients with ILC have worse clinical outcomes with late recurrences. Despite these differences, clinical trials treat HR-positive breast cancers as a single disease, and there is an unmet need for studies addressing the unique challenges faced by patients diagnosed with ILC.
PMID:33641217 | PMC:PMC8176983 | DOI:10.1002/onco.13734
View details for PubMedID 33641217
Abrupt involution induces inflammation, estrogenic signaling, and hyperplasia linking lack of breastfeeding with increased risk of breast cancer Breast cancer research : BCR
Basree MM, Shinde N, Koivisto C, Cuitino M, Kladney R, Zhang J, Stephens J, Palettas M, Zhang A, Kim HK, Acero-Bedoya S, Trimboli A, Stover DG, Ludwig T, Ganju R, Weng D, Shields P, Freudenheim J, Leone GW, Sizemore GM, Majumder S, Ramaswamy B
2019 Jul 17;21(1):80. doi: 10.1186/s13058-019-1163-7.
BACKGROUND: A large collaborative analysis of data from 47 epidemiological studies concluded that longer duration of breastfeeding reduces the risk of developing breast cancer. Despite the strong epidemiological evidence, the molecular mechanisms linking prolonged breastfeeding to decreased risk of breast cancer remain poorly understood.
METHODS: We modeled two types of breastfeeding behaviors in wild type FVB/N mice: (1) normal or gradual involution of breast tissue following prolonged breastfeeding and (2) forced or abrupt involution following short-term breastfeeding. To accomplish this, pups were gradually weaned between 28 and 31 days (gradual involution) or abruptly at 7 days postpartum (abrupt involution). Mammary glands were examined for histological changes, proliferation, and inflammatory markers by immunohistochemistry. Fluorescence-activated cell sorting was used to quantify mammary epithelial subpopulations. Gene set enrichment analysis was used to analyze gene expression data from mouse mammary luminal progenitor cells. Similar analysis was done using gene expression data generated from human breast samples obtained from parous women enrolled on a tissue collection study, OSU-2011C0094, and were undergoing reduction mammoplasty without history of breast cancer.
RESULTS: Mammary glands from mice that underwent abrupt involution exhibited denser stroma, altered collagen composition, higher inflammation and proliferation, increased estrogen receptor α and progesterone receptor expression compared to those that underwent gradual involution. Importantly, when aged to 4 months postpartum, mice that were in the abrupt involution cohort developed ductal hyperplasia and squamous metaplasia. Abrupt involution also resulted in a significant expansion of the luminal progenitor cell compartment associated with enrichment of Notch and estrogen signaling pathway genes. Breast tissues obtained from healthy women who breastfed for < 6 months vs ≥ 6 months showed significant enrichment of Notch signaling pathway genes, along with a trend for enrichment for luminal progenitor gene signature similar to what is observed in BRCA1 mutation carriers and basal-like breast tumors.
CONCLUSIONS: We report here for the first time that forced or abrupt involution of the mammary glands following pregnancy and lack of breastfeeding results in expansion of luminal progenitor cells, higher inflammation, proliferation, and ductal hyperplasia, a known risk factor for developing breast cancer.
PMID:31315645 | PMC:PMC6637535 | DOI:10.1186/s13058-019-1163-7
View details for PubMedID 31315645
A hedgehog pathway-dependent gene signature is associated with poor clinical outcomes in Luminal A breast cancer Breast cancer research and treatment
Rudolph M, Sizemore ST, Lu Y, Teng KY, Basree MM, Reinbolt R, Timmers CD, Leone G, Ostrowski MC, Majumder S, Ramaswamy B
2018 Jun;169(3):457-467. doi: 10.1007/s10549-018-4718-x. Epub 2018 Feb 20.
PURPOSE: High expression of glioma-associated oncogene homolog-1 (GLI1) is associated with poor prognosis in estrogen receptor (ER) positive breast cancers. We sought to define a GLI1-dependent gene signature in ER-positive tumors that could further stratify patients at higher risk for disease recurrence and potentially lead to novel combination therapies.
METHODS: We identified an inverse correlation between GLI1 expression and distant disease-free survival (DFS) using a dataset developed at MD Anderson Cancer Center (Hatzis dataset) containing clinical data from 508 breast cancer patients. Using a qPCR-based microarray platform, we identified genes differentially regulated by GLI1 in MCF7 cells and then determined if expression of these genes correlated with GLI1 expression in patient tumor samples. Statistical comparison between the groups was performed by ANOVA. Direct comparison of two groups was done by a two-tailed t test. Correlations between variables were done by Pearson's method.
RESULTS: Expression of GLI1 and its target genes correlated significantly with worse distant DFS in breast cancer patients with Luminal A molecular subtype. Particularly, co-expression of GLI1 with EGFR and/or SNAI1, two of the identified GLI1 targets, was predictive of worse distant DFS in this subtype. Furthermore, patients with Luminal A tumors with a high GLI1 signature had a shorter distant DFS compared to the Luminal B subtype and the outcome for this group was comparable to patients with HER2-positive or basal-like tumors.
CONCLUSION: We have identified a novel GLI1 gene signature that is associated with worse clinical outcomes among the patients with Luminal A subtype of breast cancer.
PMID:29464534 | DOI:10.1007/s10549-018-4718-x
View details for PubMedID 29464534
Erratum to: miR-29b defines the pro-/anti-proliferative effects of S100A7 in breast cancer Molecular cancer
Zhao H, Wilkie T, Deol Y, Sneh A, Ganju A, Basree M, Nasser MW, Ganju RK
2015 Nov 16;14(1):195. doi: 10.1186/s12943-015-0451-9.
miR-29b defines the pro-/anti-proliferative effects of S100A7 in breast cancer Molecular cancer
Zhao H, Wilkie T, Deol Y, Sneh A, Ganju A, Basree M, Nasser MW, Ganju RK
2015 Jan 27;14:11. doi: 10.1186/s12943-014-0275-z.
INTRODUCTION: S100A7 (Psoriasin) is an inflammatory protein known to be upregulated in breast cancer. However, the role of S100A7 in breast cancer has been elusive, since both pro- and anti-proliferative roles have been reported in different types of breast cancer cells and animal models. To date, the mechanism by which S100A7 differentially regulates breast cancer cell proliferation is still not clear.
METHODS: We used Gene Functional Enrichment Analysis to search for the determining factor of S100A7 differential regulation. We confirmed the factor and elaborated its regulating mechanism using in vitro cell culture. We further verified the findings using xenografts of human breast cancer cells in nude mice.
RESULTS: In the present study, we show that S100A7 significantly upregulates the expression of miR-29b in Estrogen Receptor (ER)-positive breast cancer cells (represented by MCF7), and significantly downregulates miR-29b in ER-negative cells (represented by MDA-MB-231) [Corrected]. The differential regulation of miR-29b by S100A7 in ER-positive and ER-negative breast cancer is supported by the gene expression analysis of TCGA invasive breast cancer dataset. miR-29b transcription is inhibited by NF-κB, and NF-κB activation is differentially regulated by S100A7 in ER-positive and ER-negative breast cancer cells. This further leads to differential regulation of PI3K p85α and CDC42 expression, p53 activation and p53-associated anti-proliferative pathways. Reversing the S100A7-caused changes of miR-29b expression by transfecting exogenous miR-29b or miR-29b-Decoy can inhibit the effects of S100A7 on in vitro cell proliferation and tumor growth in nude mice.
CONCLUSIONS: The distinct modulations of the NF-κB - miR-29b - p53 pathway make S100A7 an oncogene in ER-negative and a cancer-suppressing gene in ER-positive breast cancer cells, with miR-29b being the determining regulatory factor.
PMID:25622979 | PMC:PMC4314775 | DOI:10.1186/s12943-014-0275-z
View details for PubMedID 25622979